Evidence map›Paper›PMID 24458591›Full record

ArticlePflugers Archiv : European journal of physiology2014

cAMP-PKA inhibition of SK3 channel reduced both Ca2+ entry and cancer cell migration by regulation of SK3-Orai1 complex.

Lucie Clarysse, Maxime Guéguinou, Marie Potier-Cartereau, Grégoire Vandecasteele, Philippe Bougnoux, Stephan Chevalier, Aurélie Chantôme, Christophe Vandier

Abstract read
PubMed Publisher
In one paragraph

Article in Pflugers Archiv : European journal of physiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Store-Operated CaInternational journal of molecular sciences · 2018
    Review
  14. Article
  15. Review
  16. Article
  17. Zinc transporters and dysregulated channels in cancers.Frontiers in bioscience (Landmark edition) · 2017
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Lucie ClarysseInserm, UMR1069 "Nutrition, Croissance et Cancer", Tours, 37032, France.
Maxime Guéguinou
Marie Potier-Cartereau
Grégoire Vandecasteele
Philippe Bougnoux
Stephan Chevalier
Aurélie Chantôme
Christophe Vandier
Université de Tours · FRInserm · FRCentre Hospitalier Universitaire de Tours · FRInstitut Galien Paris-Saclay · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SK3 channel mediates the migration of various cancer cells. When expressed in breast cancer cells, SK3 channel forms a complex with Orai1, a voltage-independent Ca(2+) channel. This SK3-Orai1 complex associates within lipid rafts where it controls a constitutive Ca(2+) entry leading to cancer cell migration and bone metastases development. Since cAMP was found to modulate breast cancer cell migration, we hypothesized that this could be explained by a modulation of SK3 channel activity. Herein, we study the regulation of SK3 channel by the cAMP-PKA pathway and the consequences for SK3-dependent Ca(2+) entry and cancer cell migration. We established that the beta-adrenergic receptor agonist, isoprenaline, or the direct adenylyl cyclase activator forskolin alone or in combination with the PDE4 inhibitor, CI-1044, decreased SK3 channel activity without modifying the expression of SK3 protein at the plasma membrane. Forskolin and CI-1044 reduced the SK3-dependent constitutive Ca(2+) entry and the SK3-dependent migration of MDA-MB-435s cells. PKA inhibition with KT 5720 reduced: (1) the effect of forskolin and CI-1044 by 50 % on Ca(2+) entry and (2) SK3 activity by inhibiting the serine phosphorylation of SK3. These cAMP-elevating agents displaced Orai1 protein outside lipid rafts in contrast to SK3, which remained in the lipid rafts fractions. All together, these results show that activation of the cAMP-PKA pathway decreases SK3 channel and SK3-Orai1 complex activities, leading to a decrease in both Ca(2+) entry and cancer cell migration. This work supports the potential use of cAMP-elevating agents to reduce cancer cell migration and may provide novel opportunities to address/prevent bone metastasis.

Indexed as

Cell MovementAdrenergic beta-AgonistsAzepinesCalciumCalcium ChannelsCarbazolesCell Line, TumorColforsinCyclic AMPCyclic AMP-Dependent Protein KinasesHEK293 CellsHumansIsoproterenolMembrane MicrodomainsNiacinamideORAI1 ProteinAdrenergic beta-AgonistsAzepinesCalciumCalcium ChannelsCarbazolesCI 1044ColforsinCyclic AMPCyclic AMP-Dependent Protein KinasesIsoproterenolKCNN3 protein, humanKT 5720NiacinamideORAI1 ProteinORAI1 protein, humanPhosphodiesterase 4 InhibitorsProtein Kinase InhibitorsPyrrolesSmall-Conductance Calcium-Activated Potassium Channels

Identifiers

PMID24458591
OpenAlexW2076006649

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.